COVID-19

Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.

Patient education on the risks of the long-term illness can help overcome vaccine hesitancy.

The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.

The combination vaccine candidates will be evaluated in 2 separate phase 1/2 clinical trials.

By identifying patients at high risk for progressing to severe disease and counseling them on their treatment options, pharmacists empower patients to make informed decisions about their treatment.

The decline was attributed to continued adherence to infection prevention and control measures.

The Act is set to end at the end of 2024, which will affect pharmacists’ abilities to administer COVID-19 tests, vaccines, and treatment that are distributed by the federal government.

Evidence suggests that precautionary measures in elementary schools were able to effectively mitigate large increases in disease transmission.

Severity of a COVID-19 illness could be determined by examining autoantibodies in the nasal cavity, allowing more personalized treatment protocols.

High COVID-19 hospital caseload strain led to increases in inpatient adverse events among patients both with and without SARS-CoV-2 infection.

Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.

In children aged 12, 18, and 24 months, there was no association between maternal COVID-19 exposure and abnormal scores on a neurodevelopment screening.

Despite suggestions to the contrary in previously conducted small clinical trials, montelukast did not provide benefit in patients with COVID-19 symptoms.

The clinical hold is a result of a reported case of motor neuropathy in a phase 2 trial participant.

The increase was observed across multiple subgroups, including those with overweight or obesity and hospitalized patients.

High-resolution scans can provide a picture of a patient’s brain that typical MRIs cannot, allowing for more detailed insights into the neurological effects of COVID-19.

Healgen Rapid Check COVID-19/Flu A&B Antigen Test is the first OTC test to detect influenza to be granted a marketing authorization outside of Emergency Use Authorizations.

The discovery marks the first time an antibody has been observed to both assist and block viral infection with SARS-CoV-2.

However, the results also showed that vaccination rates were lower in those who are unmedicated for their mental illness and those with substance use disorders.

Major biomarkers for cognitive impairment were observed in hospitalized patients with neurological symptoms.

There was a detrimental relationship between COVID-19 caseload and mortality observed across multiple types of hospitals.

Although the investigators commonly detected treatment-emergent resistant variants, they were rare and transient in nature.

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

Long-term shedding of mutated variants could pose a concern for spread among the public.

Investigators reported that more than half of individuals had great knowledge about protecting themselves from COVID-19.

Though hospitalizations and test positivity remain at modest levels, wastewater analysis indicates high circulation of SARS-CoV-2, especially in western states.

In 2021, cancer diagnosis rates remained low after major disruptions during the first year of the COVID-19 pandemic.

In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.

Bezisterim, an anti-inflammatory insulin sensitizer, will be authorized to proceed to a phase 2 clinical trial.